Applied Clinical Trials brief flags standstill in peptide rulemaking
The roundup pairs the regulatory pause with items on enrollment feasibility pressure-testing and gaps in real-world evidence infrastructure.
DO
By Daniel Okafor · Regulatory Correspondent
Sep 30 06:21 ETSource: appliedclinicaltrialsonline.com
The wire
- 01Applied Clinical Trials' September 30 brief lists a peptide rulemaking standstill among its lead items, alongside trial enrollment feasibility and real-world evidence infrastructure.
- 02Sponsors and compounders tracking how peptides are classified have been waiting on rulemaking to settle which compounds can be prepared and studied.
- 03The brief is a short roundup; no new agency filing, date or docket detail is given, so the underlying status remains unchanged.
From the source
Read at appliedclinicaltrialsonline.comACT Brief: Enrollment Feasibility Pressure-Testing, RWE Infrastructure Gaps, and Peptide Rulemaking Standstill
